A pre-clinical melanoma DC vaccine study expanded endogenous DCs by subcutaneously injecting a B16 melanoma tumor engineered to secrete FLT3L (B16-FLT3L), and expanded splenic CD8+ cDC1s were collected and used as a vaccine. This evidence concerns the gene FLT3LG and neoplasm.